Invasive Ductal Carcinoma Breast: How Neoadjuvant Chemotherapy Affects the Status of Estrogen Receptor Progesterone Receptor and HER2/Neu-A Tertiary Care Centre Study

摘要

IntroductionDetermination of Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2eu in primary Invasive Ductal Carcinoma (IDC) breast is the standard of care parameter for determining treatment options. Whether or not Neoadjuvant Chemotherapy (NAC) affects the receptor status is still an unanswered question.